跳转至内容
Merck
CN
  • Cytoskeletal regulatory gene expression and migratory properties of B-cell progenitors are affected by the ETV6-RUNX1 rearrangement.

Cytoskeletal regulatory gene expression and migratory properties of B-cell progenitors are affected by the ETV6-RUNX1 rearrangement.

Molecular cancer research : MCR (2014-07-26)
Chiara Palmi, Grazia Fazio, Angela M Savino, Julia Procter, Louise Howell, Valeria Cazzaniga, Margherita Vieri, Giulia Longinotti, Ilaria Brunati, Valentina Andrè, Pamela Della Mina, Antonello Villa, Mel Greaves, Andrea Biondi, Giovanna D'Amico, Anthony Ford, Giovanni Cazzaniga
摘要

Although the ETV6-RUNX1 fusion is a frequent initiating event in childhood leukemia, its role in leukemogenesis is only partly understood. The main impact of the fusion itself is to generate and sustain a clone of clinically silent preleukemic B-cell progenitors (BCP). Additional oncogenic hits, occurring even several years later, are required for overt disease. The understanding of the features and interactions of ETV6-RUNX1-positive cells during this "latency" period may explain how these silent cells can persist and whether they could be prone to additional genetic changes. In this study, two in vitro murine models were used to investigate whether ETV6-RUNX1 alters the cellular adhesion and migration properties of BCP. ETV6-RUNX1-expressing cells showed a significant defect in the chemotactic response to CXCL12, caused by a block in CXCR4 signaling, as demonstrated by inhibition of CXCL12-associated calcium flux and lack of ERK phosphorylation. Moreover, the induction of ETV6-RUNX1 caused changes in the expression of cell-surface adhesion molecules. The expression of genes regulating the cytoskeleton was also affected, resulting in a block of CDC42 signaling. The abnormalities described here could alter the interaction of ETV6-RUNX1 preleukemic BCP with the microenvironment and contribute to the pathogenesis of the disease. Alterations in the expression of cytoskeletal regulatory genes and migration properties of BCP represent early events in the evolution of the disease, from the preleukemic phase to the clinical onset, and suggest new strategies for effective eradication of leukemia.

材料
产品编号
品牌
产品描述

Sigma-Aldrich
HEPES, ≥99.5% (titration)
Sigma-Aldrich
HEPES, BioPerformance Certified, ≥99.5% (titration), suitable for cell culture
Sigma-Aldrich
丙酮酸钠, powder, BioReagent, suitable for cell culture, suitable for insect cell culture, ≥99%
Sigma-Aldrich
丙酮酸钠, ReagentPlus®, ≥99%
Sigma-Aldrich
HEPES缓冲溶液, 1 M in H2O
Sigma-Aldrich
米非司酮, ≥98%
Sigma-Aldrich
HEPES, BioUltra, Molecular Biology, ≥99.5% (T)
Sigma-Aldrich
L - (−) -葡萄糖, ≥99%
Sigma-Aldrich
钙黄绿素-AM, suitable for fluorescence, BioReagent, ≥90% (HPLC)
Sigma-Aldrich
丙酮酸钠, powder, BioXtra, suitable for mouse embryo cell culture
Sigma-Aldrich
HEPES, BioXtra, suitable for mouse embryo cell culture, ≥99.5% (titration)
Sigma-Aldrich
丙酮酸钠, Hybri-Max, powder, suitable for hybridoma
Sigma-Aldrich
HEPES, BioXtra, pH 5.0-6.5 (1 M in H2O), ≥99.5% (titration)
Sigma-Aldrich
钙黄绿素-AM, Small Package (20 X 50 μg ), ≥90.0% (HPLC)
Sigma-Aldrich
HEPES, anhydrous, free-flowing, Redi-Dri, ≥99.5%
Sigma-Aldrich
丙酮酸钠, BioXtra, ≥99%
Sigma-Aldrich
钙黄绿素AM 溶液, 4 mM in DMSO, ≥90% (HPLC), solution
Sigma-Aldrich
丙酮酸钠, anhydrous, free-flowing, Redi-Dri, ReagentPlus®, ≥99%
Supelco
HEPES, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
HEPES, Vetec, reagent grade, 99.5%
Sigma-Aldrich
丙酮酸钠, Vetec, reagent grade, 98%